More information about ALEXION PHARMACEUTICALS INC.

Alexion is a global biopharmaceutical company focused on developing and delivering life-changing therapies for patients with devastating and rare diseases. Patients with these life-threatening diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know people's lives depend on our work. Alexion was established in the U.S. in 1992 and became a public company in 1996 (NASDAQ: ALXN). We were added to the NASDAQ-100 Index in 2011 and to the Standard & Poor's 500 Index in 2012. Alexion’s global headquarters are currently in New Haven, Conn. In September 2017, the Company announced that it would relocate its headquarters to Boston, Mass., by mid-2018 and that New Haven would serve as the Company’s Center of Excellence for its world-class complement research and process development teams. Alexion's employees around the world serve patients in approximately 50 countries.